INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference Boca Raton, FL

INmune Bio Announces Two Presentations at the

Upcoming 18th Annual CTAD Conference

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE)

-- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming

18th Clinical Trials on Alzheimer's Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.

About INmune Bio Inc.

INmune Bio Inc. is a clinical-stage biotechnology

company focused on developing treatments that target immunology and inflammation. INmune Bio has three product platforms: the Dominant-Negative

Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver

of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom , is a proprietary pooled,

allogeneic, human umbilical cord-derived mesenchymal Stromal cell (hucMSCs) platform that recently completed a blinded randomized trial

in recessive dystrophic epidermolysis bullosa. The third program, INKmune , is designed to prime a patient's natural killer

cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate

cancer. To learn more, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there

is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development

or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data,

including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro ,

and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking

statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein

are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events

and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties.

CORDstrom , XPro1595 (XPro , pegipanermin), and INKmune have either finished clinical trials, are still in clinical

trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory

body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will

be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited

to, risks and uncertainties relating to the Company's ability to produce more drug for clinical trials; the availability of substantial

additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product

commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans

and strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities

and Exchange Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q

and the Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect

any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

Chief Executive Officer

Head of Investor Relations